Investigational antiviral drugs for the treatment of COVID-19

被引：0

作者：

Vegivinti, C. T. R. ^{[1
]}

Assi, M. ^{[2
]}

Talwani, R. ^{[3
]}

Koblizek, V ^{[4
,5
]}

Burke, K. ^{[6
]}

Temesgen, Z. ^{[7
]}

机构：

[1] Manipal Acad Higher Educ MAHE, Kasturba Med Coll, Dept Gen Med, Manipal, Karnataka, India

[2] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA

[3] Univ Maryland, Div Infect Dis, Baltimore, MD 21201 USA

[4] Charles Univ Prague, Univ Hosp Hradec Kralove, Prague, Czech Republic

[5] Charles Univ Prague, Fac Med, Prague, Czech Republic

[6] Wolters Kluwer, Clin Effectiveness, Indianapolis, IN USA

[7] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN USA

来源：

DRUGS OF THE FUTURE | 2021年 / 46卷 / 09期

基金：

美国国家卫生研究院;

关键词：

COVID-19; SARS-CoV-2; Remdesivir; Hydroxychloroquine; Lopinavir/ritonavir; Ribavirin; Ivermectin; Favipiravir; Umifenovir; Camostat; Nafamostat Nitazoxanide; DAS-181; RESPIRATORY SYNDROME CORONAVIRUS; SIALIDASE FUSION PROTEIN; NAFAMOSTAT MESILATE; INTERFERON-THERAPY; RIBAVIRIN; IVERMECTIN; INHIBITOR; DAS181; RITONAVIR; INFECTION;

D O I：

10.1358/dof.2021.46.9.3293585

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov , which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.

引用

页码：697 / 710

页数：14

共 119 条

[31] Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture [J].

de Wilde, Adriaan H. ;

Jochmans, Dirk ;

Posthuma, Clara C. ;

Zevenhoven-Dobbe, Jessika C. ;

van Nieuwkoop, Stefan ;

Bestebroer, Theo M. ;

van den Hoogen, Bernadette G. ;

Neyts, Johan ;

Snijder, Eric J. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) :4875-4884

[32] Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models [J].

Delvecchio, Rodrigo ;

Higa, Luiza M. ;

Pezzuto, Paula ;

Valadao, Ana Luiza ;

Garcez, Patricia P. ;

Monteiro, Fabio L. ;

Loiola, Erick C. ;

Dias, Andre A. ;

Silva, Fabio J. M. ;

Aliota, Matthew T. ;

Caine, Elizabeth A. ;

Osorio, Jorge E. ;

Bellio, Maria ;

O'Connor, David H. ;

Rehen, Stevens ;

de Aguiar, Renato Santana ;

Savarino, Andrea ;

Campanati, Loraine ;

Tanuri, Amilcar .

VIRUSES-BASEL, 2016, 8 (12)

[33] Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series [J].

Doi, Kent ;

Ikeda, Mahoko ;

Hayase, Naoki ;

Moriya, Kyoji ;

Morimura, Naoto .

CRITICAL CARE, 2020, 24 (01)

[34] A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19 [J].

Doi, Yohei ;

Hibino, Masaya ;

Hase, Ryota ;

Yamamoto, Michiko ;

Kasamatsu, Yu ;

Hirose, Masahiro ;

Mutoh, Yoshikazu ;

Homma, Yoshito ;

Terada, Masaki ;

Ogawa, Taku ;

Kashizaki, Fumihiro ;

Yokoyama, Toshihiko ;

Koba, Hayato ;

Kasahara, Hideki ;

Yokota, Kazuhisa ;

Kato, Hideaki ;

Yoshida, Junichi ;

Kita, Toshiyuki ;

Kato, Yasuyuki ;

Kamio, Tadashi ;

Kodama, Nobuhiro ;

Uchida, Yujiro ;

Ikeda, Nobuhiro ;

Shinoda, Masahiro ;

Nakagawa, Atsushi ;

Nakatsumi, Hiroki ;

Horiguchi, Tomoya ;

Iwata, Mitsunaga ;

Matsuyama, Akifumi ;

Banno, Sumi ;

Koseki, Takenao ;

Teramachi, Mayumi ;

Miyata, Masami ;

Tajima, Shigeru ;

Maeki, Takahiro ;

Nakayama, Eri ;

Taniguchi, Satoshi ;

Lim, Chang Kweng ;

Saijo, Masayuki ;

Imai, Takumi ;

Yoshida, Hisako ;

Kabata, Daijiro ;

Shintani, Ayumi ;

Yuzawa, Yukio ;

Kondo, Masashi .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)

[35] DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient [J].

Drozd, D. R. ;

Limaye, A. P. ;

Moss, R. B. ;

Sanders, R. L. ;

Hansen, C. ;

Edelman, J. D. ;

Raghu, G. ;

Boeckh, M. ;

Rakita, R. M. .

TRANSPLANT INFECTIOUS DISEASE, 2013, 15 (01) :E28-E32

[36] Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection [J].

Du Yin-Xiao ;

Chen Xiao-Ping .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (02) :242-247

[37] Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 [J].

Eastman, Richard T. ;

Roth, Jacob S. ;

Brimacombe, Kyle R. ;

Simeonov, Anton ;

Shen, Min ;

Patnaik, Samarjit ;

Hall, Matthew D. .

ACS CENTRAL SCIENCE, 2020, 6 (05) :672-683

[38]

Elgazzar A., 2020, EFFICACY SAFETY IVER, DOI [DOI 10.21203/RS.3.RS-100956/V3, 10.21203/rs.3.rs-100956/v1]

[39] Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques [J].

Falzarano, Darryl ;

de Wit, Emmie ;

Rasmussen, Angela L. ;

Feldmann, Friederike ;

Okumura, Atsushi ;

Scott, Dana P. ;

Brining, Doug ;

Bushmaker, Trenton ;

Martellaro, Cynthia ;

Baseler, Laura ;

Benecke, Arndt G. ;

Katze, Michael G. ;

Munster, Vincent J. ;

Feldmann, Heinz .

NATURE MEDICINE, 2013, 19 (10) :1313-+

[40] Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin [J].

Falzarano, Darryl ;

de Wit, Emmie ;

Martellaro, Cynthia ;

Callison, Julie ;

Munster, Vincent J. ;

Feldmann, Heinz .

SCIENTIFIC REPORTS, 2013, 3

← 1 2 3 4 5 6 7 8 9 10 →